Skip to main content
. 2021 Dec 20;12:791348. doi: 10.3389/fimmu.2021.791348

Figure 2.

Figure 2

COVID-19 patients with positive anti-MDA5 Ab exhibit severe clinical performance. (A), Comparison of the percentage of COVID-19 patients with non-severe (mild & moderate) and severe performance in anti-MDA5 Ab negative (Anti-MDA5 Ab Neg) and anti-MDA5 Ab positive (Anti-MDA5 Ab Pos) group. (B–J), Comparison of clinical and demographic features of COVID-19 patients in anti-MDA5 Ab negative and positive groups. (B), survival rate; (C), total disease course; (D), the percentage of organ dysfunction; (E), age; (F), lymphocyte number; (G), neutrophils number; (H), albumin levels; (I), the ratio of neutrophils versus lymphocytes (NLR); (J), the ratio of C-reactive protein (CRP) versus albumin (CAR). The numbers of COVID-19 patients in each group are indicated underneath. P values were determined by using unpaired, two-sided Mann-Whitney U-test and χ2 test. P < 0.05, *; P < 0.01, **; P < 0.0001, ****.